Mannitol Injection IP 25% w/v

Therapeutic Use:

Mannitol Injection IP 25% w/v is a sterile, non-pyrogenic hyperosmotic solution used to reduce elevated intracranial and intraocular pressure. It is commonly indicated in the management of cerebral edema, glaucoma, and for promoting diuresis in acute renal failure or toxic substance elimination.

Mechanism of Action:

Mannitol acts as an osmotic diuretic. When administered intravenously, it increases the osmotic pressure of plasma, drawing water from tissues (including the brain and eyes) into the bloodstream. It also reaches the renal tubules where it inhibits reabsorption of water and electrolytes, thereby increasing urine output. This dual action relieves pressure and aids in detoxification through enhanced diuresis.

Key Benefits:

✔ Rapid reduction of intracranial pressure in traumatic brain injury or stroke.
✔ Decreases intraocular pressure in acute glaucoma attacks.
✔ Promotes forced diuresis in cases of drug toxicity or renal dysfunction.
✔ Prevents renal damage by maintaining urine flow in early acute renal failure.
✔ Supports emergency treatment protocols for cerebral and ocular emergencies.

Regulatory Compliance:

WHO-GMP | EU-GMP | cGMP | GLP

Note: Approvals are currently under process with relevant authorities.